BJ
NBIX icon

BlackRock Japan’s Neurocrine Biosciences NBIX Stock Holding History

BlackRock Japan’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-217
Closed -$10K – 1384
2016
Q2 		$10K Sell
217
-859
-80% -$39.5K ﹤0.01% 1278
2016
Q1 		$43K Sell
1,076
-475
-31% -$18.8K ﹤0.01% 1058
2015
Q4 		$88K Buy
1,551
+258
+20% +$13.1K ﹤0.01% 928
2015
Q3 		$51K Hold
1,293
– – ﹤0.01% 972
2015
Q2 		$62K Buy
1,293
+155
+14% +$6.57K ﹤0.01% 1039
2015
Q1 		$45K Buy
1,138
+707
+164% +$25.3K ﹤0.01% 1081
2014
Q4 		$10K Buy
+431
New +$8.17K ﹤0.01% 1269
2014
Q2 		– Sell
-793
Closed -$13K – 1362
2014
Q1 		$13K Buy
+793
New +$13.6K ﹤0.01% 1317

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock Japan's NBIX Position: Q3 2016 in Review

BlackRock Japan sold out of Neurocrine Biosciences (NBIX) in Q3 2016, closing a stake of 217 shares — an estimated $10K sold.

BlackRock Japan first reported a position in NBIX in Q1 2014 and held it in 8 quarters. The position peaked at $88K in Q4 2015. 244 funds tracked by Wall St. Rank hold NBIX as of Q3 2016.

  • BlackRock Japan reported no remaining Neurocrine Biosciences position as of Q3 2016 after selling out during the quarter.
  • BlackRock Japan sold 217 Neurocrine Biosciences shares in Q3 2016, an estimated $10K.
  • BlackRock Japan first reported a position in Neurocrine Biosciences in Q1 2014 and held it in 8 quarters.
  • BlackRock Japan's Neurocrine Biosciences position peaked at $88K in Q4 2015.
  • 244 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2016.

Based on BlackRock Japan's 13F filing for Q3 2016, filed 8 Nov 2016.